- The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
-
Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, Sathekge M
- KMID: 2516692
- Nucl Med Mol Imaging.
- 2021 Jun;55(3):136-140.
- doi: 10.1007/s13139-021-00696-5
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 ( 177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably... -
- CITED
-
- Close
- SHARE
-
- Close
